Hande Sultan SAHINER

Dr. Hande Sultan SAHINER

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Clinical Nutrition
Verified
Journal Article
Closed access
MBMurat Boyacioglu
Murat Boyacioglu
CKCavit Kum
Cavit Kum
SSSELİM SEKKİN
SELİM SEKKİN
HSHande Sultan SAHINER
Hande Sultan SAHINER
HAHamdi Avci
Hamdi Avci
UKUmit Karademir
Umit Karademir

27 May 2015 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
DADilek Aksit
Dilek Aksit
HSHande Sultan SAHINER
Hande Sultan SAHINER
SSSELİM SEKKİN
SELİM SEKKİN
MBMurat Boyacioğlu
Murat Boyacioğlu
VCVeli Yilgor Cirak
Veli Yilgor Cirak
Cengiz GokbulutCengiz Gokbulut
Cengiz Gokbulut
The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12–16 months old and weighing 20–32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites.

1 December 2018 in Theriogenology
Verified
Journal Article
Closed access
ZNZahid Naseer
Zahid Naseer
EAEjaz Ahmad
Ejaz Ahmad
HSHande Sultan SAHINER
Hande Sultan SAHINER
EEErkmen Tuğrul Epikmen
Erkmen Tuğrul Epikmen
MFMuhammad Fiaz
Muhammad Fiaz
MAMelih Aksoy
Melih Aksoy

1 December 2014 in Experimental and Toxicologic Pathology
Verified
Journal Article
Closed access
MBMurat Boyacioglu
Murat Boyacioglu
SSSELİM SEKKİN
SELİM SEKKİN
CKCavit Kum
Cavit Kum
DKDeniz Korkmaz
Deniz Korkmaz
FKFunda Kiral
Funda Kiral
FAFerda Akar
Ferda Akar

1 January 2015 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Closed access
SSSELİM SEKKİN
SELİM SEKKİN
EIEda Duygu İpEk
Eda Duygu İpEk
MBMurat Boyacioğlu
Murat Boyacioğlu
CKCavit Kum
Cavit Kum
ÜKÜmit Karademi̇r
Ümit Karademi̇r
HBHulki Başaloğlu
Hulki Başaloğlu

18 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
UEUfuk Eryilmaz
Ufuk Eryilmaz
BDBuket Demirci
Buket Demirci
SASaliha Aksun
Saliha Aksun
MBMurat Boyacioglu
Murat Boyacioglu
CACagdas Akgullu
Cagdas Akgullu
MBMehmet Bilgen
Mehmet Bilgen
This study examined the value of blood marker S100A1 in detecting cardiotoxicity induced by chemotherapy agents; trastuzumab and lapatinib, in normal rat heart. The rats were divided into three groups: control (n = 8, no treatment), T (n = 8, one time ip treatment with 10 mg/kg trastuzumab) and L (n = 8, oral treatment with 100 mg/kg/day lapatinib for 7 days). The activities of oxidative stress parameters Malondialdehyde (MDA), Superoxide dismutase (SOD), Catalase (CAT) and Glutathione (GSH) were measured from the extracted cardiac tissues. The levels of troponinI and S100A1 expressions were measured from blood samples. All biomarkers responded to the treatments as they exhibited alterations from their normative values, validating the chemically induced cardiotoxicity. S100A1 expression attenuated significantly (75%), which made the sensitive detection of cardiotoxicity feasible. Assessment of cardiotoxicity with S100A1 may be a valuable alternative in clinical oncology of cancers in some organs such as breast and prostate, as they do not overexpress it to compete against.